Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases
IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's proprietary mRNA–LNP platform. HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Innorna, a clinical‑stage biotech company advancing RNA medicines, today announced that...
Meiwu Technology Co Ltd Announces $14 Million Registered Direct Offering
SHENZHEN, China, March 17, 2026 /PRNewswire/ -- Meiwu Technology Co Ltd (NASDAQ: WNW) (the "Company"), today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of 6,999,996 of the Company's ordinary shares, no par value each (the "Shares") at a purchase price of $2.00 per share in a...
Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal
HIGHLIGHTS Oral presentation on key results from the Co-PSMA (NCT06907641) Investigator-Initiated Trial (IIT) was delivered by Prof Louise Emmett (St Vincent's Hospital Sydney) at the European Association of Urology (EAU) Congress 2026 on the 16th of March 2026 in London, UK. Co-PSMA trial data has also been accepted for publication in...
Metabolon Collaborates with The Michael J. Fox Foundation to Advance Multiomic Analyses for Parkinson’s Research
Partnership supports expanded biomarker discovery efforts within MJFF's Parkinson's Progression Markers Initiative MORRISVILLE, N.C., March 17, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a collaboration with The Michael J....
Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models
- In a head-to-head cyclic adenosine monophosphate (cAMP) activation assay vs. eloralintide, oral small molecule amylin receptor agonist ASC39 demonstrated similar selectivity and potency to that of eloralintide. EC50 for human amylin 1 receptor (hAMY1R) was 21.4 pM and 21.2 pM for ASC39 and eloralintide, respectively. EC50 for human calcitonin receptor...
Global Aesthetic Trends Evolve Toward ‘Anti-Sagging’: The Expansion of the Structural Skin Laxity Improvement and Liquid Type PCL Collagen Stimulator Market
SEOUL, South Korea, March 17, 2026 /PRNewswire/ -- The global medical aesthetics market is rapidly shifting toward an "Anti-Sagging" paradigm, focusing on improving the fundamental causes of skin laxity. While traditional aesthetic approaches primarily addressed external signs of aging—such as wrinkle reduction and volume correction—the Anti-Sagging trend focuses on the structural causes of aging: the decrease of collagen within...
Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference
SUZHOU, China and MÖLNDALS, Sweden, March 17, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences. Following...
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027
SUZHOU, China, March 17, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and VEGFR2, for the treatment of advanced malignant solid tumors. JSKN027 is the company's fifth ADC candidate...
Dr Cho Li Wei of LW Cho Endocrine Clinic Marks 27 Years of Clinical Practice and Multilingual Care
SINGAPORE, March 17, 2026 /PRNewswire/ -- Dr Cho Li Wei, leading LW Cho Endocrine Clinic, is marking 23 years in endocrinology and 27 years in clinical practice, with a continued focus on bridging language gaps in specialist medical care. The clinic serves patients across conditions including diabetes, thyroid disorders, polycystic ovary syndrome (PCOS), osteoporosis, menstrual disorders, and pituitary disorders. Consultations...
BioCina Initiates Comprehensive Manufacturing Program for Patrys’ Proprietary Injectable Therapeutic to Alleviate Delirium
PERTH, Australia, March 17, 2026 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry, Manufacturing, and Controls) program for the advancement of RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment...
